Fund Holdings — SR ONE CAPITAL MANAGEMENT, LP

Total Portfolio Value
$691.41M
Total Bought
$81.11M
Total Sold
$40.69M
Net Transaction
+$40.42M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
CRISPR Therapeutics AG(CRSP)1,048,9512,038,763+989,81251,021132,13219.11%+81,111
Zenas BioPharma, Inc(ZBIO)4,911,5394,911,539047,593109,03615.77%+61,443
Arcellx, Inc.
COMMON STOCK
2,346,6302,346,6300154,526192,65827.86%+38,133
Mineralys Therapeutics Inc.(MLYS)3,127,9332,113,933-1,014,00042,32180,16011.59%+37,839
Design Therapeutics, Inc.(DSGN)6,526,4766,526,476021,99449,1447.11%+27,150
ORIC Pharmaceuticals, Inc.(ORIC)4,514,9294,514,929045,82754,1797.84%+8,353
Oruka Therapeutics, Inc(ORKA)430,330430,33004,8248,2751.20%+3,451
enGene Holdings Inc.
COM
747,750747,75002,7225,1070.74%+2,385
Alumis Inc.1,959,8961,959,89605,8807,8201.13%+1,940
Nkarta, Inc.(NKTX)3,333,3333,333,33305,5336,9001.00%+1,367
Oculis Holding AG(OCS)322,500322,50006,2605,6700.82%-590
KALA Bio, Inc.(KALA)598,9400-598,9402,8510—-2,851
ARS Pharmaceuticals, Inc.(SPRY)4,012,9034,012,903070,02540,3305.83%-29,695
Page 1 of 1
SR ONE CAPITAL MANAGEMENT, LP — 13F Holdings — Q3 2025 | TickerTrail